Ac immune reports q3 2020 financial results and provides business update

Lausanne, switzerland, nov. 13, 2020 (globe newswire) -- ac immune sa (nasdaq: aciu), a swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for q3 2020 and provided a business update. the company ended the third quarter with chf 246.6 million in cash, which ensures operations are fully financed through q1 2024 allowing the company to advance our clinical and preclinical projects to key value inflection points while investing further in our diverse pipeline.
ACIU Ratings Summary
ACIU Quant Ranking